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Summary The roles of age and sex and their relationship to other prognostic factors were studied in 117
chronic myeloid leukaemia (CML) and in 256 chronic lymphocytic leukaemia (CLL) patients. Survival in
CML was not related either to age at diagnosis or to sex. In contrast, the CLL patients classified into four age
strata (<50, 50-59, 60-69, >70 years) had an expected median survival (EMS) of 142, 101, 85 and 33
months respectively (X2 for heterogeneity = 35.59, P <0.0005; X2 for trend = 25.09, P <0.0005). Prognostic
power was independent of sex, Rai stages, total tumour mass score (TTM), TTM distribution pattern,
anaemia, thrombocytopenia, serum immunoglobulins and response to therapy. The relative survival rate (the
ratio of patient's EMS and EMS in age- and sex-matched general population) was 0.40 in CLL patients and
0.13 in CML patients. Relative survival was more reduced in older CLL patients than in younger ones (0.37 vs
0.47, respectively), whereas relative survival was less reduced in older CML patients than in younger ones (0.18
vs 0.12, respectively). The results show that the age is a significant independent prognostic factor in CLL but
not in CML. The difference in the effects of age on prognosis in CLL and CML most probably reflects the
fundamental differences in their respective pathogeneses.
A number of prognostic factors have been identified to
influence survival in chronic leukaemias (Talpaz et al., 1988;
Binet et al., 1981; Paolino et al., 1984; Kantarjian et al.,
1988). Additionally, age and sex may also be important in
predicting prognosis. The role of age and sex and their
relation to other prognostic factors in chronic leukaemias
are, however, controversial. In chronic myeloid leukaemia
(CML) Tura et al. (1981) found an adverse influence of age
on survival in their 'CML/73' series, but not in their 'Bolog-
na' series. Multivariate analysis done by Silver et al. (1987)
indicated that age and sex were important for predicting
survival. Dameshek (1967) has postulated that chronic lym-
phocytic leukaemia (CLL) runs a more malignant course in
younger patients. This was, however, challenged by others
who found a shorter survival in older patients (Zippin et al.,
1973; Boggs et al., 1966; Galton, 1966). Recently (Catovsky
et al., 1989) showed that age and sex were important prog-
nostic factors in CLL. This controversy might originate in
the imbalanced distribution of other prognostic factors in the
respective series.
This study was done in an attempt to evaluate the prog-
nostic powers of age and sex in chronic leukaemias in
unselected patients and to evaluate the relationship of other
prognostic factors to age and sex.
Patients and methods
Patients
One hundred and seventeen CML and 256 CLL patients
followed at the Department of Medicine 'Dr 0. Novosel' in
the period from 1966 to 1982 were evaluated. Therapy was
during the observation period fairly uniform for each disease,
consisting of chlorambucil for CLL and busulphan for CML.
There were no difference in the treatment approach due to
age or sex.
Criteriafor diagnosis
CML was diagnosed according to the conventional
haematological criteria. Low alkaline phosphatase activity in
granulocytes supported the diagnosis. No cytogenetic studies
were mandatory for diagnosis. CLL was diagnosed by sus-
tained lymphocytosis in peripheral blood of more than
5.0 x IO' 1` accompanied with more than 40% lymphocytes
in bone marrow.
Statistical methods
The prognosis was evaluated by measuring survival from
diagnosis to death from all causes. Probability of survival
was calculated by the product limit actuarial method (Kaplan
& Meier, 1958). Statistical significance of the difference
between two or more survival probabilities was tested for
heterogeniety and for trend by the longrank test (Peto et al.,
1977). The expected median survival (EMS) of a subset of
patients was computed by dividing the median survival of
whole CLL group by the relative death rate (O/E) of parti-
cular subset. The adjustment for the explanatory variable(s)
was performed according to method of Peto et al. (1977).
The continuous quantitative variables such as age, TTM-size,
haemoglobin concentration and platelet count were stratified
into as few strata as possible to obtain maximal prognostic
discrimination.
Because the prognostic power of age was found only in
CLL, the relationship between age and other prognostic fac-
tors in CLL was studied in details.
Classification ofother prognosticfactors in CLL
Rai classification was used for clinical staging of patients in
CLL (Rai et al., 1975).
Total tumour mass score (TTM) was adopted for the
assessment of the tumour cell burden. TTM is a sum of: TM,
the square root of the absolute number of peripheral blood
lymphocytes per nl; TM2 the diameter of the largest palpable
lymph node in centimetres and TM3 the enlargement of the
spleen below the left costal margin in centimetres (Jaksic &
Vitale, 1981). The score above 9 was considered a high
tumour mass. Patients were further classified as 'leukaemic'
when TMI>TM2 + TM3 or 'Iymphoma like' when TM1 <
TM2 + TM3 (Jaksic & Vitale, 1981).
Anaemia was defined by the haemoglobin concentration of
less than 105 g 1-l for males and less than 95 g -' for
females. Thrombocytopenia was defined by platelet count of
less than 100 x 109 1' for both sex.
The findings of serum immunoglobulins were classified as
follows: (a) normal - the quantity of IgG 700-1,700 mg, IgA
113-562 mg and IgM 55-250 mg without evident spike in
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electrophoresis; (b) hypoimmunoglobulinemia - any of Ig
classes below normal level; (c) hyperimmunoglobulinemia-
any of Ig classes above normal level; (d) reduced hetero-
geneity ('M' spike) in electrophoresis of serum proteins
regardless of hypo- or hyperimmunoglobulinemia was
classified as finding of monoclonal proteins (Jaksic et al.,
1985). If both hyper and hypo values were present in the
same patient, the finding was classified according to the
predominant aberration.
Response to therapy was classified as (a) complete response
- defined by the decrease of TTM below the diagnostic
threshold (score of 2.3) along with the absence of anaemia
and/or thromocytopenia; (b) partial response is defined by
decrease of TTM for more than 50% of maximal value; (c)
non responding patients were those who failed to meet
criteria for (a) or (b) (Jaksic & Vitale, 1981).
Results
Age
The median age of 117 CML patients was 44 years. Thirty-
four per cent of patients were at diagnosis older than 50
years and 15% were older than 60 years. The difference
among the seven strata (each decade, starting with the
second) with respective EMS of 28, 85, 41, 61, 40, 41 and 30
was statistically non significant (X2 for heterogeneity = 6.18,
d.f. = 6, NS; x2 for trend = 0.70, d.f. = 1, NS). No statistical
significance was reacheed even after pooling the strata
together. Adjustment for sex did not substantially alter the
predictive power of age. When applied to all the seven strata
the respective EMS were: 32, 79, 62, 37, 40 and 31 month (X2
for heterogeneity = 5.4, d.f. = 6, NS; x2 for trend= 0.025,
d.f. = 1, NS). The similar finding was obtained when adjust-
ment for sex was applied to the two strata with the cut-off
point at 50 years (EMS were 53 vs 37, respectively: x2 = 2.22,
NS).
The distribution of 256 CLL patients at diagnosis into four
strata and the respective survival probability is shown in
Table I. Eighty-seven per cent of patients were at diagnosis
older than 50 years, 60% were older than 60 years. The
median age was 62 years. The expected median survival for
the four age strata was 142, 101, 85, 33 months, respectively
(X2 for heterogeneity = 35.59, d.f. = 3, P <0.0005; X2 for
trend = 25.09, d.f. = 1, P <0.0005). No significant difference
for heterogeneity was found among first three groups, so that
the maximal prognostic discrimination was obtained when
the patients were stratified into two groups with the cut-off
point at 70 years. The patients younger than 70 years had an
EMS of 97 months as compared to older patients who had
an EMS of 33 months (2= 34.34, relative risk = 2.97,
P <0.0005). When adjusted for sex minimal changes in EMS
were observed (younger patients = 99 months, older
patients = 32 months; x2 = 34.93, relative risk 3.04, P <0.0005).
Sex
Fifty-two per cent of CML patients were males. The
difference in EMS between males and females (38 vs 55) was
not statistically significant. No improvement of the sex prog-
nostic value was obtained after an adjustment for age.
Sixty-five per cent of CLL patients were males. Females
fared better than males (EMS/adjusted for age/of 91 vs 61
months respectively; x2 = 3.94, relative risk = 1.48, P <0.05).
Without an adjustment performed for the age the sex predic-
tive power was below statistically significance (EMS of 90 vs
62, x2 = 3.40, NS).
Relation to other prognosticfactors
Age was found to be a strong prognostic factor in CLL but
not in CML. Therefore, the relationship between age and
other prognostic factors was studied in CLL. The prognostic
power of age was studied without and with an adjustment
performed for clinical stage according to Rai, TTM-size,
TTM-distribution, anaemia, thrombocytopenia, serum
immunoglobulins and response to therapy. After performed
adjustments the relative risk remained essentially unchanged
in the range of 2.48 to 3.14. Furthermore, when the prognos-
tic significance of each of the listed prognostic factors was
evaluated without and with an adjustment performed for age
distribution, no substantial alterations in their respective pro-
gnostic powers were observed.
Comparison ofpatients survival with the survival in general
population
In Table II the EMS in CLL and CML are compared to
EMS of age- and sex-matched general population in Yugo-
slavia. The expected survival in CLL is longer than in CML
and the median age at diagnosis is higher in CLL than in
CML. Patients with CLL survive about 40%, whereas CML
patients survive only about 13% of the expected survival in
general population.
Older CLL patients live shorter than the younger ones, i.e.
their absolute survival is significantly shorter. Moreover,
when compared to age- and sex-matched general population,
the relative survival in older CLL patients appears shorter
(0.37) than the relative survival expectancy in younger
patients (0.47). In contrast, the opposite was found in CML.
Older patients showed a tendency to live shorter than
younger patients, i.e. their absolute survival tended to be
shorter although the difference was not statistically
significant. However, the relative survival was longer in older
(0.18) than in younger patients (0.12).
Discussion
This study has shown that the prognostic significance of age
in chronic leukaemias is different in CML as compared to
CLL. We did not find association between age and sex of
patients and the survival in CML. This supports the finding
of Tura et al. (1981) who found sex to be unrelated to the
survival in both of their series. These authors also found no
association between age and survival in their 'Bologna' series
as distinct from their 'CML/73' series in which age negatively
influenced the prognosis. In the later series the patients were
treated with splenectomy and polychemotherapy which might
explain shorter survival in older age groups, perhaps due to
some adverse effect to aggressive therapeutic approach. When
their series were pooled together in prognostic power of age
was below the level of statistical significance.
Table I Survival probability by age in chronic lymphocytic leukaemia
Age n % 0 R OIE EMS x2 het. x2 trend
49 30 (13) 7 14.007 0.50 142
50-59 73 (27) 25 35.932 0.70 101 35.59 25.09
60-69 81 (32) 31 36.804 0.84 85 d.f. = 3 d.f. = 1
70- 72 (28) 44 20.257 2.17 33 (P <0.0005)
Total 256 (100) 107 107.000 1.00 71
n = number ofpatients, 0 = observed number ofdeaths, E = expected number of
deaths, EMS = expected median, survival in months, O/E = relative death rate,
X = logrank statistic, d.f. = degrees of freedom.AGE AND SEX IN CHRONIC LEUKAEMIAS 347
Table II Comparison of patient's survival with the survival in age and sex
matched general population
Age Median EMSJ EMS2 Rel. survival
(yrs) n % age (mo) (mo) (EMSl/EMS2)
CLL (all) 256 (100) 62 71 177 0.40
- 69 184 (72) 59 97 205 0.47
70- 72 (28) 74 33 92 0.37
CML (all) 117 (100) 44 46 348 0.13
- 49 77 (66) 36 51 432 0.12
50- 40 (34) 57 38 216 0.18
n = number of patients, EMS1 = expected median survival in patients,
EMS2 = EMS in age and sex matched general population.
In contrast to our findings in CML, we found a significant
reduction in the absolute survival in older CLL patients. This
is in line with findings reported in the literature (Rai et al.,
1975; Catovsky et al., 1989; Bernardou, 1973) but in contrast
with the view of Dameshek (1967) who postulated more
malignant disease course in younger patients. In addition, we
found a borderline significance of the prognostic value of sex
in CLL patients with the tendency of females to survive
better than in males. Similar results were reported in the
literature (Zippin et al., 1973; Hansen, 1973; Catovsky et al.,
1989).
A significant difference in the absolute survival among
CLL patients of different age could be either (1) related to
unequal distribution of CLL characteristics known to
influence survival among various age groups or (2) unrelated
to the major CLL characteristics. A number of disease
characteristics has been identified to influence survival in
CLL (Osgood, 1964; Planinc-Peraica et al., 1984). Thus the
shorter survival in older patients could be either due: (a) to a
more advanced stage of the disease at diagnosis or (b) to a
more accelerated course of the disease with a lesser response
to therapy or (c) to some other adverse prognosis factors. To
evaluate these possibilities we analysed the prognostic power
of age without and with an adjustment performed for un-
equal distribution of disease stage according to Rai, TTM-
size, TTM-distribution pattern, haemoglobin level, platelet
count, serum immunoglobulin concentration and response to
therapy. After the adjustment performed no significant reduc-
tion in the prognostic power of age was observed, indicating
the lack of any significant direct relationship between the age
and the distribution of the disease characteristics analysed. In
other words the age appears independent of other prognostic
factors and vice versa, the prognostic factors analysed
appeared independent of age. This supports the second alter-
native postulated i.e. that the observed difference in absolute
survival among different age groups is unrelated to CLL
characteristics.
Moreover, when the median survival in CLL patients was
compared to age- and sex-matched general population in
Yugoslavia, a reduction to about 40% ofexpected survival in
general population was found. No substantial difference was
found between the younger and older patients with the
respect to the degree of EMS reduction, although the EMS
reduction was more pronounced in older patients. This
indicates that the age exerts the same kind of adverse
influence on survival in CLL patients as in the general
population, the effect in CLL being more pronounced. This is
in keeping with the analyses of the causes of deaths in CLL
by Boggs et al. (1966) who found that the majority of
patients died due to complicating infections, some unknown
cause or a condition apparently unrelated to CLL. The
adverse influence of age to survival could also be related to a
more frequent presence of associated chronic diseases in
older patients (Paolino et al., 1984). This contrasts the causes
of death in CML where the vast majority of patients die
from a disease transformation to a more malignant condi-
tion, most frequently a blastic transformation (Tura et al.,
1981). In comparison to age- and sex-matched general
population the reduction of expected survival is more pro-
nounced in younger than in older CML patients.
These findings suggest a fundamental difference in biology
of chronic leukaemias. CML behaves like a typical neoplasm
'killing' the host after progressing to a more malignant condi-
tion. Virtually all patients die from the disease progression
which is unrelated to age and sex. In contrast, the CLL 'kills'
the patients in a function of their age. Older patients live
shorter than younger patients, similar to the situation in
general population where older individuals live shorter than
younger individuals. Likewise, the females survive better than
males in CLL, but this is the case also in general population.
Therefore the adverse effect of male sex to survival in CLL is
comparable to the effect of sex in general population.
Accordingly the results suggest that CLL increases the
general risk of dying or somehow 'decrease the viability' of
patients. In this respect CLL is more similar to 'premature
ageing' than to a typical neoplasm.
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